A U.S. Court has dismissed a lawsuit filed by HDT Bio Corp against Pune-based Emcure Pharmaceuticals.
A Federal court in Seattle, Washington, has dismissed the lawsuit filed by HDT against Emcure regarding Covid-19 vaccine technology.
HDT had named Emcure as a party in the suit, alleging non-payment of royalties and demanded a compensation of at least $950 million.
When contacted a company spokesperson said, "The ruling vindicates our stand".
Emcure had contended in the court that the lawsuit was illegitimate and brought by HDT to compensate for its business shortcomings.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
HDT Bio had alleged that the Pune-based firm had stolen its vaccine technology which it had licensed to Gennova for manufacture and distribution in India.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.